12 completed, 7 terminated, 6 recruiting, 4 unknown. 34 Phase 1, 14 Phase 2.
Follow Castration-resistant Prostate Cancer: new trials by email Literature Review of Castration-resistant Prostate Cancer trials Research Report on Castration-resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer JANX014 - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Janux Therapeutics | 43 | 2026-04-15 | 2026-09-03 |
| A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC 161Tb RAD402 - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Radiopharm Theranostics, Ltd | 73 | 2026-03-05 | 2026-04-01 |
| A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types IDE034 - Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer | Phase 1 | Recruiting | IDEAYA Biosciences | 150 | 2026-02-24 | 2026-06-18 |
| Study of DCC-2812 in Participants With Advanced Genitourinary Cancers DCC-2812 - Renal Cell Carcinoma, Urothelial Carcinoma | Phase 1 | Recruiting | Deciphera Pharmaceuticals, LLC | 60 | 2025-08-27 | 2026-08-18 |
| Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC PSMA-UCAR T (BRL-302) - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 | Active not recruiting | Shanghai Changzheng Hospital | 3 | 2025-03-27 | 2026-07-23 |
| GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy Investigational Agent Administration - Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Virginia Commonwealth University | 30 | 2025-02-18 | 2026-01-27 |
| 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Baptist Health South Florida | 2024-10-01 | 2024-09-19 | |
| Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study Injection, 161Tb-SibuDAB,1GBq, Injection, 177Lu-PSMA-I&T, 1GBq, Injection, 161Tb-SibuDAB, Dose Escalation - Castration-resistant Prostate Cancer | Phase 1 | Recruiting | University Hospital, Basel, Switzerland | 25 | 2024-02-20 | 2024-08-14 |
| A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects SHR3680 tablets - Castration-Resistant Prostate Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 52 | 2023-04-26 | 2023-05-15 |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors XmAb®808, Keytruda® (pembrolizumab) - Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma | Phase 1 | Completed | Xencor, Inc. | 60 | 2022-12-14 | 2025-08-07 |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients Abiraterone Acetate - Prostate Cancer, Metastatic Cancer | Phase 1 | Unknown | National University Hospital, Singapore | 10 | 2021-11-30 | 2024-01-08 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors SM08502, Abiraterone, Prednisone - Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer | Phase 1 | Terminated | Biosplice Therapeutics, Inc. | 30 | 2021-11-03 | 2024-08-09 |
| The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC Coenzyme A Combined With Abiraterone, Abiraterone - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Unknown | Jiangnan University | 50 | 2021-03-18 | 2021-04-09 |
| Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC Polaprezinc group, Control group - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Jiangnan University | 12 | 2021-01-06 | 2023-07-11 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
| Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients Enzalutamide or Abiraterone or Apalutamid - Castration-Resistant Prostate Cancer | Phase 1 | Completed | Kangpu Biopharmaceuticals, Ltd. | 16 | 2019-11-26 | 2023-07-18 |
| A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer nab-paclitaxel, carboplatin - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 44 | 2019-11-01 | 2019-11-04 |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma GB1275, nab-paclitaxel and gemcitabine, pembrolizumab - Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma | Phase 1 | Terminated | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | 61 | 2019-08-13 | 2022-08-18 |
| A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Talazoparib, Temozolomide - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 16 | 2019-07-11 | 2026-08-24 |
Showing 20 of 34. Sign in to see all of them.
Prostatic Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Transitional Cell (4) · Endometrial Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Hepatocellular (3) · Ovarian Neoplasms (3) · Stomach Neoplasms (3) · Esophageal Squamous Cell Carcinoma (2) · Melanoma (2) · Neoplasm Metastasis (2)
Neoplasms by Site (19) · Neoplasms (18) · Urogenital Diseases (18) · Male Urogenital Diseases (17) · Urogenital Neoplasms (17) · Genital Diseases (16) · Genital Diseases, Male (11) · Genital Neoplasms, Male (11) · Prostatic Diseases (11) · Breast Diseases (9) · Neoplasms by Histologic Type (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8)
abiraterone (3) · enzalutamide (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Docetaxel (2) · Prednisone (2) · pembrolizumab (2) · spartalizumab (2) · Abiraterone Acetate (1) · Carboplatin (1) · Control Groups (1) · Crizotinib (1) · Cyclophosphamide (1) · Gemcitabine (1) · IFL protocol (1)
Jiangnan University (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Novartis Pharmaceuticals (2) · Aragon Pharmaceuticals, Inc. (1) · Arcus Biosciences, Inc. (1) · Baptist Health South Florida (1) · Bayer (1) · Biosplice Therapeutics, Inc. (1) · Cancer Research UK (1) · Dana-Farber Cancer Institute (1) · Deciphera Pharmaceuticals, LLC (1) · Emmanuel Antonarakis, MD (1) · Exelixis (1) · GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. (1) · IDEAYA Biosciences (1)
United States (20) · United Kingdom (6) · China (5) · Australia (4) · France (4) · Belgium (3) · Netherlands (3) · Spain (3) · Canada (2) · Italy (2) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1) · Moldova (1)
Adrian VS Hill (1) · Alin Chirindel, MD (1) · Andre Bergman, MD, PhD (1) · Andrew Protheroe (1) · Christopher Sweeney, MD (1) · Darrin Beaupre, MD, PhD, CMO (1) · Dingwei Ye, M.D. (1) · Edmund Chiong, MBBS, PhD (1) · Freddie Hamdy (1) · Joel Eisner (1)
PMID 26854432, PMID 27091421, PMID 31082669, PMID 33744986, PMID 34491815, PMID 35690072, PMID 38204489, PMID 39965176, PMID 40906325
2015 (1), 2023 (1)